PARX HEAL Stock

Equities

PRLX

US69916A1051

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for PARX HEAL -.--% -.--%
Sales 2018 0.01 Sales 2019 0.13 Capitalization 14.07M
Net income 2018 16M Net income 2019 -12M EV / Sales 2018 1,568,116,279 x
Net Debt 2018 2.95M Net Debt 2019 3.52M EV / Sales 2019 136,778,344 x
P/E ratio 2018
1.35 x
P/E ratio 2019
-0.94 x
Employees -
Yield 2018 *
-
Yield 2019
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Parallax Health Sciences Inc. Announces Executive Changes CI
Parallax Health Sciences Inc. Terminates Sonia Choi as Interim CEO CI
Parallax Health Sciences, Inc. Appoints Sonia Choi as Interim Chief Executive Officer CI
Parallax Health Sciences, Inc. Announces Executive Changes CI
Parallax Health Sciences Inc. Announces Resignation of Paul R. Arena as Chief Executive Officer CI
Parallax Health Sciences Inc. Announces Management Changes CI
Parallax Health Sciences, Inc. Announces Resignation of Capt. E. William Withrow Jr. from its Board and Chair of the Compensation Committee, Deputy Chair of the Audit Committee and Co-Chair of the Governance Committee CI
Parallax Health Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2019 CI
Parallax Health Sciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Parallax Health Sciences, Inc. Announces Executive Changes CI
Parallax Health Sciences, Inc. Launches Secure Good Health Outcomes Telehealth Application for Immediate Free Download CI
Parallax Health Sciences, Inc. Updates Progress on Proprietary COVID-19 Rapid Test CI
Parallax Health Sciences, Inc. Receives Approval on its Registration Into U.S. Government's System for Award Management, CI
Parallax Health Sciences, Inc. announced that it expects to receive $5 million in funding CI
Parallax Health Sciences, Inc. Announces Resignation of David Appell as Chief Operating Officer CI
More news
Parallax Health Sciences, Inc. focuses on personalized patient care through the use of the Company's Compound Pharmacy (Roxsan, Inc.) and eventually through the diagnostic testing platform capable of diagnosing and monitoring various health issues. The Company's segments include Retail Pharmacy Services (RPS) and Corporate. The RPS segment provides a range of pharmacy services, including retail, compounding and fertility medications. The Corporate segment provides management and administrative services to support the Company. The RPS segment dispenses prescription drugs, both through local channels by direct delivery, as well as mail order. The RPS segment also sells an assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, seasonal merchandise and convenience foods, through the Company's pharmacy. It holds interests in Quality of Life Peace of Mind (QOLPOM). The QOLPOM Hub is a personal medication dispensing and remote monitoring solution.
Sector
-
More about the company